Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017141927 - AZOLE-SUBSTITUTED PYRIDINE COMPOUND

Publication Number WO/2017/141927
Publication Date 24.08.2017
International Application No. PCT/JP2017/005388
International Filing Date 14.02.2017
IPC
C07D 401/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
A61K 31/4439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/46 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
468-Azabicyclo octane; Derivatives thereof, e.g. atropine, cocaine
A61K 31/4709 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines containing further heterocyclic rings
CPC
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
A61K 31/4709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines and containing further heterocyclic rings
A61K 31/498
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Applicants
  • 大正製薬株式会社 TAISHO PHARMACEUTICAL CO., LTD. [JP]/[JP]
Inventors
  • 田中 宏明 TANAKA, Hiroaki
  • 坊野 綾子 BOHNO, Ayako
  • 濱田 まこと HAMADA, Makoto
  • 伊藤 勇次 ITO, Yuji
  • 小橋 陽平 KOBASHI, Yohei
  • 川村 円 KAWAMURA, Madoka
Agents
  • 小野 新次郎 ONO, SHINJIRO
  • 山本 修 YAMAMOTO, Osamu
  • 宮前 徹 MIYAMAE, Toru
  • 中西 基晴 NAKANISHI, Motoharu
  • 山口 晶子 YAMAGUCHI, Akiko
Priority Data
2016-02587815.02.2016JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) AZOLE-SUBSTITUTED PYRIDINE COMPOUND
(FR) COMPOSÉ DE PYRIDINE À SUBSTITUANT AZOLE
(JA) アゾールで置換されたピリジン化合物
Abstract
(EN)
The present invention provides a compound represented by formula [I'], which has the effect of inhibiting an enzyme which produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I']: the structure represented by formula [III] is any one of the structures represented by formulae [IV]; R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3 alkanediyl, or formula -O-CH2CH2-; ring A represents (a) a substituted C4-6 cycloalkyl, (b) a nitrogen atom-containing, substituted, 4- to 6-membered, and saturated heterocyclyl, (c) a substituted phenyl, (d) a substituted pyridyl, (e) a substituted 2,3-dihydrobenzofuran, (f) an oxygen atom-containing, 4- to 6-membered, and saturated heterocyclyl, etc.)
(FR)
La présente invention concerne un composé représenté par la formule [I'], qui possède l'effet d'inhibition d'une enzyme produisant de l'acide 20-HETE, ou un sel pharmaceutiquement acceptable de celui-ci. Dans la formule [I']: la structure représentée par la formule [III] est l'une quelconque parmi les structures représentées par les formules [IV]; R1 représente un atome d'hydrogène, un atome de fluor, un groupe méthyle, et analogues; R2, R3, et R4 représentent chacun indépendamment un atome d'hydrogène, un atome de fluor ou méthyle; W représente une liaison simple, alcanédiyle C1-3, ou la formule -O-CH2CH2-; le cycle A représente (a) un cycloalkyle C4-6 substitué, (b) un hétérocyclyle contenant des atomes d'azote substitué et saturé, de 4 à 6 chaînons, (c) un phényle substitué (d) un pyridyle substitué, (e) un groupe 2,3-dihydrobenzofurane substitué, (f) un hétérocyclyle saturé contenant des atomes d'oxygène, de 4 à 6 chaînons, et analogues
(JA)
本発明は、20-HETEを産生する酵素を阻害する作用を有する下記式[I']で表される化合物又はその製薬学的に許容される塩を提供する。(上記式[I']中、 下記式[III]で表される構造は、下記式群[IV]のいずれかの構造を示し; Rは、水素原子、フッ素原子、メチル等を示し; R、R、及びRは、独立して、水素原子、フッ素原子、又はメチルを示し; Wは、単結合、C1-3アルカンジイル、又は式-O-CHCH-を示し; 環Aは、(a)置換されているC4-6シクロアルキル、(b)置換されている窒素原子を含む4から6員の飽和のヘテロシクリル、(c)置換されているフェニル、(d)置換されているピリジル、(e)置換されている2,3-ジヒドロベンゾフラン、(f)酸素原子を含む4から6員の飽和のヘテロシクリル等を示す。)
Latest bibliographic data on file with the International Bureau